Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
U S X P - should get action today
Universal Express Announces Agreement To Purchase Jacksonville, Florida `Megastation' Oil And Gas Distributor
NEW YORK, Jul 19, 2006 (BUSINESS WIRE) -- Universal Express Inc. (OTCBB: USXP), has announced the signing of an agreement to purchase Jacksonville Oil Company LLC, a North Florida oil and gas retailer. The company, located in Jacksonville, is comprised of eight super stations that include both mini-marts and numerous co-branding agreements. In calendar year 2005, the Company had in excess of $20,000,000 in gross sales. The first 2 quarters of 2006 shows a substantial increase over the same time period of 2005.
"At current levels," said Richard A. Altomare, President and CEO of Universal, "we will see a benefit in excess of $1,000,000 in EBITDA from this purchase."
The purchase price is $15,800,000, subject to the Company obtaining an appropriate first mortgage on the properties. An escrow deposit of $250,000 was paid by the Company, subject to the completion of due diligence within 90-days.
"The acquired company is one of the best-managed, cleanest, high-tech operations we saw in viewing potential acquisitions in this industry," said Mr. Altomare.
Universal Express Inc. has targeted the fuel distribution sector recently as a result of its decision to vertically integrate its luggage delivery, courier, and aircraft operations. In March of this year the company announced a letter of intent to purchase a large, South Florida-based retailer and "jobber." This acquisition is pending.
"We expect to affect a substantial increase in revenues from the Jacksonville properties and through the introduction of some of Universal's existing services and products into the stations," said Mr. Altomare. "Further, as our Florida presence grows we want to introduce the same corporate and community responsibility here as we have in corporate central as well as our other subsidiaries and partners," he further stated.
About Universal Express
Universal Express, Inc. is a 22 year old logistics and transportation conglomerate with multiple developing subsidiaries and services. For additional information please visit www.usxp.com.
I M J X - tommorows runner imho ..eom
I M J X - going ..eom
in USXP - bounce..eom
in USXP - bounce ...eom
Oilexco Completes Drilling and Completion Phase of Brenda Field Development
6/22/2006
CALGARY, ALBERTA, Jun 22, 2006 (CCNMatthews via COMTEX News Network) --
Oilexco Incorporated ("Oilexco") (TSX:OIL) (AIM:OIL) announces that it has completed on schedule, and on budget, the initial drilling and completion phase on it's 100% owned Brenda Field (Block 15/25b) development located in the UK Central North Sea. This phase consisted of the drilling and completion of three horizontal production wells: 15/25b-D1, 15/25b-D2 and 15/25b-D3. In addition, the top-hole section of a fourth (reserve) production well 15/25a-D4 was drilled into the reservoir and cased to the point of horizontal position. The timing of the drilling of the horizontal leg of this well is a function of reservoir performance. This operation is tentatively scheduled for the first quarter of 2007.
The three horizontal production wells were flow tested as part of the well completion and clean-up program.
The flow test results are as follows:
1. The production well 15/25b-D1 flowed oil at a maximum rate of 6,301 Bbl/d, through a 66/64" choke, at 509 psi flowing tubing pressure.
2. The production well 15/25b-D2 flowed oil at a maximum rate of 9,765 Bbl/d, through a 64/64" choke, at 521 psi flowing tubing pressure.
3. The production well 15/25b-D3 flowed oil at a maximum rate of 10,417 Bbl/d, through a 64/64" choke, at 552 psi flowing tubing pressure.
Based on calculated well sand-face productivity indices, calculated well flow rates normalized to a 8% reservoir pressure drawdown are as follows:
1. The production well 15/25b-D1 would have a calculated oil flow of 10,000 Bbl/d, based on a calculated sand-face productivity index of 50 Bbl/d per psi drawdown.
2. The production well 15/25b-D2 would have a calculated oil flow of 14,000 Bbl/d, based on a calculated sand-face productivity index of 70 Bbl/d per psi drawdown.
3. The production well 15/25b-D3 would have a calculated oil flow of 20,000 Bbl/d, based on a calculated sand-face productivity index of 100 Bbl/d per psi drawdown.
All oil recovered was 40 degrees API sweet crude consistent with oil recovered on previous Brenda flow tests. Oil flow rates were restricted by the test equipment utilized and government mandated oil volume burn limit regulations. No water or sand was produced in the three flow tests.
The three completed Brenda production wells are currently capped with sub-sea production Christmas Trees awaiting tie-in to the Brenda manifold. This operation is expected to commence on schedule after the completion of the sub-sea installation phase of the Brenda/Nicol development in August.
"The completion flow tests for the three wells exceeded our expectations. Their sand-face productivity indexes and normalized flow calculations suggest a possible combined production rate of 44,000 barrels of oil per day, though we will restrict their flow once in production to adhere to good reservoir management practices," said Oilexco President and CEO Arthur Millholland. "We are also very pleased with how smoothly this phase of the Brenda development was completed," he added. "It is a testament to our philosophy of in house project management that the production wells were completed on schedule, and on budget, in a market that has experienced cost inflation, lengthy delays and significant cost overruns. The Oilexco team continues to work diligently to ensure ensuing project targets are achieved on schedule, and on budget, with first oil continuing to be targeted early in the fourth quarter."
The Sedco 712 is now located on the company's 70% owned Nicol Field (Block 15/25a) where drilling operations have commenced on the first Nicol horizontal production well 15/25/a-N1. The drilling and completion phase of the Nicol Field development is expected to take approximately 28 days.
After completion of operations at Nicol, the Transocean Sedco 712 will move to Block 21/23a to conduct further appraisal drilling on the Eocene Tay Sand oil accumulation discovered in May 2006. A cluster of four appraisal well-bores is planned to be drilled on the south-half of the structure. In addition the name of this oil accumulation has been changed from Disraeli to Sheryl. After completion of appraisal drilling in Block 21/23a, the Transocean Sedco 712 will continue with appraisal drilling at Shelly located in Block 22/2b (100%) and Kildare located in 15/26b (50%) respectively.
O I L X F - 35,000 bbls per day !!!
http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?view=CN&storyID=2006-07-18T160451Z_...
only 70 days till first production
imagine going from 200 bbls per day to 35,000 barrels per day
x 75 bucks hugee cash flows
15- 20 BUCKS A SHARE in my opinion only
OILXF OR OIL. TO IN CANADA
REUTERS Canada's Oilexco aims for Oct N.Sea oilfield start
LONDON, July 18 (Reuters) - Canada's Oilexco aims
to start production from its UK North Sea Brenda and Nicol
fields in October and expects output to reach 30,000 barrels per
day next year, a company executive said on Tuesday.
The development is Oilexpo's first as an operator in the
North Sea.
Britain hopes new entrants such as Oilexpo to the ageing
North Sea industry wil help slow declining output in the
region.
"Our target is October this year for first oil," Oilexco
Investor Relations Manager Rob Elgie told Reuters on Tuesday.
Production was expected to peak at 35,000 bpd later when
another well is drilled and connected, he said.
Oil industry group the UK Offshore Operators Association
(UKOOA) forecast on Tuesday that combined UK oil and gas output
would rise 300,000 barrels of oil equivalent per day (boepd) to
3.3 million boepd in 2007, the first annual rise in output since
1999.
Record oil prices have helped fuel a late-life boom in the
North Sea industry, and the UK received a record number of
applicants
Brenda and Nicol oil production will be tied back to the
Balmoral floating production vessel operated by Canadian Natural
Resources and be pumped through the BP-owned
Forties pipeline to the UK.
Oilexpo is 100 percent owner of the Brenda field and 70
percent owner of Nicol. ConocoPhillips and Agip
own the remaining 30 percent, but have agreed to relinquish
ownership after they have lifted a total 1.25 million barrels
from the field's production.
Oilexpo's current North Sea ouptut is a few hundred barrels
per day, which it receives as a non-operating equity holder in
the Balmoral and Glamis fields.
(c) Reuters 2006. All rights reserved. Republication or redistribution of
Reuters content, including by caching, framing or similar means, is
expressly prohibited without the prior written consent of Reuters. Reuters
and the Reuters sphere logo are registered trademarks and trademarks of
S C U R .........EOM
S C U R - ready to go again //eom
O P W V - bid 7.62 ask 7.58 ????lololol
watch O P W V - bids are above ask !!!
in S C U R - for bounce ...eom
in O P W V - a big bounce coming ..eom
in O P W V --$7.61 - oversold ..eom
F F D G - 5 million o/s
if you like gllc you love this one
expect promo soon
heads up
blym vs usxp
i remember everyone saying the exact same thing about usxp
- dont buy it at 0002x 0003
we seen what happened there right?
blym is more of a real company that usxp that ill argue all day long ...lolol
good luck
P O Z N- chart loooks ready ..eom
P O Z N - huge news
New Data Show Investigational Migraine Therapy Demonstrates Effective Treatment of Migraine-Associated Neck and Sinus Pain
6/26/2006
Single Tablet Combination Therapy Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen Sodium Provides Rapid and Sustained Relief
LOS ANGELES, June 26, 2006, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
(NYSE: GSK; Nasdaq: POZN) An investigational migraine treatment demonstrates effective treatment of migraine-associated neck pain/discomfort and sinus pain/pressure, according to new data presented at the Annual Meeting of the American Headache Society (AHS) in Los Angeles. In addition, use of the compound was statistically superior in producing pain-free rates as early as 30 minutes. Furthermore, significantly more patients reached pain-free status at two hours; this result was sustained for 24 hours without the use of additional medicine. This single tablet combination therapy -- currently under review with the U.S. Food and Drug Administration (FDA) under the proposed trade name Trexima(TM) -- contains sumatriptan 85 mg, as the succinate salt, formulated with RT Technology(TM), and naproxen sodium 500 mg.
"These data suggest that a single treatment designed to target multiple mechanisms of migraine may be an effective option for many patients," said Stephen Silberstein, MD, director of the Jefferson Headache Center and lead study investigator. "In particular, we're excited because these studies show promise at treating associated symptoms of migraine such as neck pain and discomfort and sinus pain and pressure, which can be difficult to alleviate."
Recent data indicate that the pathophysiology of migraine is complex and that migraine is not merely a vascular problem, but a result of a chain of events that are both vascular and neurological. These events develop early in the migraine process, often long before a patient actually feels the sensation of headache pain. Migraine pain is believed to be induced not only by the widening of blood vessels, or vasodilation, but also by inflammation, leading to nociception (perception of pain) and central and peripheral sensitization.
About the Studies
The studies evaluated the efficacy and tolerability of sumatriptan 85mg, formulated with RT Technology(TM), and naproxen sodium 500 mg versus placebo for the treatment of mild migraine pain. The data were derived from two identical randomized, multi-center, double-blind, placebo-controlled parallel group, single attack (treating mild pain within one hour of onset) trials of adult migraineurs in the U.S. Study results indicated:
-- Neck pain and discomfort decreased significantly at two hours for the
compound versus placebo in study 1 (35 and 44 percent) and study 2
(28 and 54 percent).
-- Sinus pain and pressure decreased significantly at two hours for the
compound versus placebo in study 1 (19 and 33 percent) and study 2
(23 and 38 percent).(1)
-- More patients were pain free at two hours in both studies (52 and
51 percent) compared to placebo (17 and 15 percent) and sustained
pain-free response was maintained for significantly more patients
(45 and 40 percent), without the use of a rescue medication, to
24 hours, compared to placebo (12 and 14 percent).
-- The compound was effective in rapidly eliminating migraine pain, as
measured by pain-free rates at 30 minutes, one hour, two hours and
four hours.
-- Incidence of migraine associated symptoms (nausea, phonophobia
(sensitivity to sound) and photophobia (sensitivity to light)) was
lower with the compound than with placebo.
-- The compound was generally well-tolerated. In both studies, only
nausea (3 and 4 percent) and dizziness (1 and 2 percent) were reported
in at least 2 percent of patients who took the compound versus placebo
(1 and 2 percent for nausea, 0 and < 1 percent for dizziness).
"This data illustrates how the new understanding of migraine pathophysiology is leading to the development of effective treatments with an early and sustained effect," continued Dr. Silberstein.
Multiple Mechanisms of Migraine
Understanding the multiple mechanisms of migraine may explain why migraine sufferers often experience different types of symptoms. For example, during a migraine, stimulation of the trigeminal nerve (fifth cranial nerve, carrying sensory information from the face) may cause referral of pain to any of the nerve's three branches, resulting in facial pain. It can also cause referral of pain to the sensory nerves of the posterior head and neck, resulting in neck pain.
About Imitrex(R) (sumatriptan succinate) Tablets
Imitrex is a prescription medication indicated for the acute treatment of migraine in adults. Imitrex should only be used when a clear diagnosis of migraine has been established. Patients should not take Imitrex if they have certain types of heart disease, history of stroke or TIAs, peripheral vascular disease, Raynaud syndrome, or blood pressure that is uncontrolled. Patients with risk factors for heart disease, such as high blood pressure, high cholesterol, diabetes or are a smoker, should be evaluated by a doctor before taking Imitrex. Very rarely, certain people, even some without heart disease, have had serious heart related problems. Patients who are pregnant, nursing, or taking medications should talk to their doctor.
About Naproxen Sodium
Naproxen sodium is a non-steroidal anti-inflammatory drug (NSAID) and is contained in Anaprox(R), Anaprox DS(R), Naprelan(R), Aleve(R) and in a number of over-the-counter medications. Naproxen sodium is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile arthritis. It is also indicated for the treatment of tendinitis, bursitis, acute gout and for the management of pain and primary dysmenorrhea. Naproxen-containing products should not be used by patients who have had allergic reactions to any product containing naproxen, nor in patients in whom aspirin or other NSAIDs induce the syndrome of asthma, rhinitis, and nasal polyps. Patients who have a history of peptic ulcer or gastrointestinal bleeding, kidney problems, uncontrolled hypertension or heart failure should consult a physician before using naproxen-containing medications. NSAIDs may cause increased risk of serious cardiovascular thrombotic events, myocardial infarction and stroke. This risk may increase with duration of use and in patients with cardiovascular disease or risk factors for cardiovascular disease. Serious gastrointestinal toxicity such as bleeding, ulceration and perforation can occur at any time in patients treated chronically with NSAID therapy and physicians should remain alert for such effects even in the absence of previous GI tract symptoms. Patients who are pregnant or are nursing should consult a physician before use of a naproxen-containing medication.
About GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For detailed company information, see GlaxoSmithKline's website: http://www.gsk.com .
About POZEN
POZEN (Nasdaq: POZN) is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain related conditions. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN".
For detailed company information, including copies of this and other press releases, see POZEN's website: http://www.pozen.com .
P O Z N - pre market ...eom
BLYM - great news....eom
HUGE NEWS!!! 44,000 BBLS PER DAY
americans can buy it on the pink sheets under OILXF
Oilexco Completes Drilling and Completion Phase of Brenda Field Development
Thursday June 22, 1:02 pm ET
CALGARY, ALBERTA--(CCNMatthews - June 22, 2006) - Oilexco Incorporated ("Oilexco") (TSX:OIL - News; AIM:OIL) announces that it has completed on schedule, and on budget, the initial drilling and completion phase on it's 100% owned Brenda Field (Block 15/25b) development located in the UK Central North Sea. This phase consisted of the drilling and completion of three horizontal production wells: 15/25b-D1, 15/25b-D2 and 15/25b-D3. In addition, the top-hole section of a fourth (reserve) production well 15/25a-D4 was drilled into the reservoir and cased to the point of horizontal position. The timing of the drilling of the horizontal leg of this well is a function of reservoir performance. This operation is tentatively scheduled for the first quarter of 2007.
The three horizontal production wells were flow tested as part of the well completion and clean-up program.
The flow test results are as follows:
1. The production well 15/25b-D1 flowed oil at a maximum rate of 6,301 Bbl/d, through a 66/64" choke, at 509 psi flowing tubing pressure.
2. The production well 15/25b-D2 flowed oil at a maximum rate of 9,765 Bbl/d, through a 64/64" choke, at 521 psi flowing tubing pressure.
3. The production well 15/25b-D3 flowed oil at a maximum rate of 10,417 Bbl/d, through a 64/64" choke, at 552 psi flowing tubing pressure.
Based on calculated well sand-face productivity indices, calculated well flow rates normalized to a 8% reservoir pressure drawdown are as follows:
1. The production well 15/25b-D1 would have a calculated oil flow of 10,000 Bbl/d, based on a calculated sand-face productivity index of 50 Bbl/d per psi drawdown.
2. The production well 15/25b-D2 would have a calculated oil flow of 14,000 Bbl/d, based on a calculated sand-face productivity index of 70 Bbl/d per psi drawdown.
3. The production well 15/25b-D3 would have a calculated oil flow of 20,000 Bbl/d, based on a calculated sand-face productivity index of 100 Bbl/d per psi drawdown.
All oil recovered was 40 degrees API sweet crude consistent with oil recovered on previous Brenda flow tests. Oil flow rates were restricted by the test equipment utilized and government mandated oil volume burn limit regulations. No water or sand was produced in the three flow tests.
The three completed Brenda production wells are currently capped with sub-sea production Christmas Trees awaiting tie-in to the Brenda manifold. This operation is expected to commence on schedule after the completion of the sub-sea installation phase of the Brenda/Nicol development in August.
"The completion flow tests for the three wells exceeded our expectations. Their sand-face productivity indexes and normalized flow calculations suggest a possible combined production rate of 44,000 barrels of oil per day, though we will restrict their flow once in production to adhere to good reservoir management practices," said Oilexco President and CEO Arthur Millholland. "We are also very pleased with how smoothly this phase of the Brenda development was completed," he added. "It is a testament to our philosophy of in house project management that the production wells were completed on schedule, and on budget, in a market that has experienced cost inflation, lengthy delays and significant cost overruns. The Oilexco team continues to work diligently to ensure ensuing project targets are achieved on schedule, and on budget, with first oil continuing to be targeted early in the fourth quarter."
The Sedco 712 is now located on the company's 70% owned Nicol Field (Block 15/25a) where drilling operations have commenced on the first Nicol horizontal production well 15/25/a-N1. The drilling and completion phase of the Nicol Field development is expected to take approximately 28 days.
After completion of operations at Nicol, the Transocean Sedco 712 will move to Block 21/23a to conduct further appraisal drilling on the Eocene Tay Sand oil accumulation discovered in May 2006. A cluster of four appraisal well-bores is planned to be drilled on the south-half of the structure. In addition the name of this oil accumulation has been changed from Disraeli to Sheryl. After completion of appraisal drilling in Block 21/23a, the Transocean Sedco 712 will continue with appraisal drilling at Shelly located in Block 22/2b (100%) and Kildare located in 15/26b (50%) respectively.
BLYM - whats the short intrest currently ?
anyone have a update on the current short on the stock
nice squueeeze coming i think
IN POZN @ $6.67...EOM
GNBT- short squeeeze all being bought above the ask!
G N B T - big pre markt action ...eom
H O T J - heads up $1.82
i said head up on P O Z N last week at 5.40 now 7.20
now in my opinion only
H O T J ..... big bounce coming in my opinion ....
http://stockcharts.com/h-sc/ui?s=hotj
P O Z N - BUYING ABOVE THE ASK!!
current price 7.50 orders going thru at$ 8.00
wow ....
GNBT -- Russell Microcap(TM) Index June 30
Com ($0.001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Generex Biotechnology Scheduled to Be Added to Russell Microcap Index
TORONTO, Jun 19, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it is scheduled to join the Russell Microcap(TM) Index when Russell Investment Group reconstitutes its family of U.S. indexes on June 30, according to a preliminary membership list posted Friday on www.russell.com.
"We believe that our inclusion in the Russell Microcap Index reflects the significant progress we have made in the past year in the development of drug delivery systems for the treatment and prevention of diabetes and avian influenza," said Anna Gluskin, Generex's President and Chief Executive Officer. "With more than $50 million in cash on our balance sheet and the only buccal insulin delivery system approved and on the market, we feel we are well positioned to continue our growth. Our inclusion in the Russell Microcap Index will increase the Company's visibility with investors and institutions that rely on the Russell indexes as part of their investment strategy."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.8 trillion in assets currently are benchmarked to them. Investment managers who oversee these funds purchase shares of member stocks according to that company's weighting in the particular index.
Russell, a global leader in multi-manager investment services, provides investment products and services in 44 countries. Russell manages more than $167 billion in assets and advises clients worldwide representing $2.4 trillion. Founded in 1936, Russell is a subsidiary of Northwestern Mutual and is headquartered in Tacoma, Wash., with additional offices in New York, Toronto, London, Paris, Singapore, Sydney, Auckland and Tokyo.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Contact:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: (800) 391-6755
(416) 364-2551
Ed Lewis
CEOcast, Inc.
Phone: 1 (212) 732-4300
SOURCE: Generex Biotechnology
Copyright 2006 Market Wire, All rights reserved.
P O Z N - breaking looose...eom
G N B T - gapping pre market ...eom
here goes P O Z N again .. $6.91..eom
P O Z N - gone wild!!.eom
P O Z N - flying .. short cover?
G N B T - 1.44 heads up ...eom
POZN - $15 target
Analyst Eun K. Yang with Jefferies and Company Inc. wrote in a Monday note to clients that the stock is oversold. Yang predicts the drug will not cause any serious safety issues because its main ingredients are two already marketed pain relieving drugs, though he noted that the exact nature of the FDA's inquiry is unknown.
Yang rated the stock at "Buy" and also lowered his price target to $15 from $20. He predicts Trexima, which is Pozen's lead product candidate, will be on the market in early 2008, about 15 months later than previously anticipated.
P O Z N --chart looks good for $$$..eom
G N B T - ready for another pop ...eom
POZN - bounce coming imho ...eom
in GNBT <<<< oversold bounce coming ...imho